Skip to main content
Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRSN ISIN · US59045L1061 LEI · 529900VWD5VDZ7PVOS22 US Manufacturing
Open in API
Filings indexed 700 across all filing types
Latest filing 2021-05-10 Share Issue/Capital Cha…
Country US United States of America
Listing US MRSN

About Mersana Therapeutics, Inc.

https://www.mersana.com/

Mersana Therapeutics, Inc. is a clinical-stage company focused on discovering and developing life-changing antibody-drug conjugates (ADCs) for patients fighting cancer. The company utilizes its proprietary and differentiated ADC platforms, which incorporate both cytotoxic and immunostimulatory payloads, to develop its pipeline. These platforms are designed to customize and optimize ADCs, aiming to overcome the limitations of first-generation technologies by improving efficacy and tolerability. Mersana is advancing a portfolio of ADC candidates to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
FORM S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Mersana Therapeutics, Inc. It registers additional shares of common stock under the company's 2017 Stock Incentive Plan and inducement stock option awards. The document includes detailed information about the securities to be registered, calculation of registration fees, incorporation by reference of prior filings, indemnification provisions, and exhibits. Form S-8 is a registration statement used for securities issued under employee benefit plans and stock incentive plans. This type of filing is related to share issuance and capital changes rather than financial performance reports, management changes, or other categories. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length is substantial (15,000 characters), and it contains the full registration statement, not just an announcement or certification, so it is not RPA or RNS. Confidence is high due to the clear identification of the form and content.
2021-05-10 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 10, 2021, reporting the results of operations and financial condition for the first quarter ended March 31, 2021. It specifically states that a press release announcing the financial results is furnished as an exhibit. The document itself is short (3738 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis. According to the rules, initial announcements of quarterly financial results with key highlights only are classified as Earnings Release (ER).
2021-05-10 English
10-Q
Interim / Quarterly Report
2021-05-10 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-04-28 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-04-28 English
DEFA14A
Regulatory Filings
2021-04-27 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.